Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CS1001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase Ib arm | EXPERIMENTAL | arms 1. Phase Ib: advanced or refractory solid tumors; |
| Phase II arm | EXPERIMENTAL | arms 2.Phase II: subjects with tumor of specific types |
| Name | Type | Description |
|---|---|---|
| CS1001 | DRUG | One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W). |
| Regorafenib | DRUG | One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes. |
Inclusion Criteria: * All participants must have unresectable advanced or metastatic tumors that have histologic or cytologic documentation confirmed. * Participant must have at least one measurable lesion by CT or MRI per RECIST 1.1; radiographic tumor assessment should be performed within 28 days...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CS1001 is an investigational small molecule being studied for the treatment of advanced refractory solid tumors. It is being evaluated in combination with regorafenib in patients with advanced or refractory solid tumors. The drug is in Phase 1 clinical development and is not yet approved.
The specific molecular target of CS1001 has not been disclosed. It is a small molecule being studied in oncology for advanced refractory solid tumors. The drug is being evaluated in combination with regorafenib in a Phase 1 clinical trial.
CS1001 is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker BAYRY. The drug is currently in Phase 1 clinical development for advanced refractory solid tumors.
CS1001 is in Phase 1 clinical development. It is an investigational drug being studied for advanced refractory solid tumors. The drug is not approved and is still undergoing clinical trials to evaluate its safety and efficacy.
CS1001 has one completed Phase 1 clinical trial, NCT04200404, which studied CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors. The trial enrolled 19 participants in Australia and has been completed.
No, CS1001 is not the same as regorafenib. CS1001 is an investigational small molecule being studied in combination with regorafenib, which is an approved drug, in a Phase 1 clinical trial for advanced refractory solid tumors.